Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level

Shotaro Enomoto, Hideyuki Tamai, Masashi Oka, Naoki Shingaki, Tatsuya Shiraki, Machiko Takeuchi, Hisanobu Deguchi, Hirohito Magari, Izumi Inoue, Mikitaka Iguchi, Kimihiko Yanaoka, Kenji Arii, Mitsuhiro Fujishiro, Naohisa Yahagi, Hiroshi Yotsuyanagi, Masao Ichinose

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aims: To compare twice-daily interferon (IFN)-β administration and once-daily IFN-α-2b administration as induction therapy in ribavirin combination therapy in chronic hepatitis C with a high viral load of genotype-1b hepatitis C virus (HCV). Methods: Sixty-one chroniche patitis patients with a high viral load of genotype-1b HCV were randomly divided into three groups: group A was given IFN-β 6 MU induction therapy twice daily for 2 weeks; group B was given IFN-α-2b 6 MU induction therapy once daily for 2 weeks; and group C was given no induction therapy. All three groups were then given IFN-α-2b 6 MU 3days/week for the rest of the 24-week study period. Ribavirin was given for the entire 24-week study period. Results: Although the cumulative HCV-RNA negative rates tended to be higher in group A than in group B, the differencewas not significant. The HCV-RNA negative rate at week 2 was significantly higher in groups A and B than in group C (P<0.05). The sustained virological response (SVR) rate was 16% overall, 21% for groups A and B, and 5% for group C; the SVR rate of groups A plus B tended to be higher than that of group C (P=0.093). Conclusions: There was no difference between the effects ofthe two induction therapies; potent induction therapy does achieve higher early viral clearance but not a higher SVR rate.

Original languageEnglish
Pages (from-to)692-700
Number of pages9
JournalHepatology Research
Volume37
Issue number9
DOIs
Publication statusPublished - 2007 Sep
Externally publishedYes

Fingerprint

Ribavirin
Chronic Hepatitis C
Hepacivirus
Interferons
Genotype
RNA
Viral Load
Therapeutics

Keywords

  • Chronic hepatitis C
  • Genotype 1b
  • Induction therapy
  • Interferon-α-2b
  • Interferon-β
  • Ribavirin

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level. / Enomoto, Shotaro; Tamai, Hideyuki; Oka, Masashi; Shingaki, Naoki; Shiraki, Tatsuya; Takeuchi, Machiko; Deguchi, Hisanobu; Magari, Hirohito; Inoue, Izumi; Iguchi, Mikitaka; Yanaoka, Kimihiko; Arii, Kenji; Fujishiro, Mitsuhiro; Yahagi, Naohisa; Yotsuyanagi, Hiroshi; Ichinose, Masao.

In: Hepatology Research, Vol. 37, No. 9, 09.2007, p. 692-700.

Research output: Contribution to journalArticle

Enomoto, S, Tamai, H, Oka, M, Shingaki, N, Shiraki, T, Takeuchi, M, Deguchi, H, Magari, H, Inoue, I, Iguchi, M, Yanaoka, K, Arii, K, Fujishiro, M, Yahagi, N, Yotsuyanagi, H & Ichinose, M 2007, 'Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level', Hepatology Research, vol. 37, no. 9, pp. 692-700. https://doi.org/10.1111/j.1872-034X.2007.00112.x
Enomoto, Shotaro ; Tamai, Hideyuki ; Oka, Masashi ; Shingaki, Naoki ; Shiraki, Tatsuya ; Takeuchi, Machiko ; Deguchi, Hisanobu ; Magari, Hirohito ; Inoue, Izumi ; Iguchi, Mikitaka ; Yanaoka, Kimihiko ; Arii, Kenji ; Fujishiro, Mitsuhiro ; Yahagi, Naohisa ; Yotsuyanagi, Hiroshi ; Ichinose, Masao. / Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level. In: Hepatology Research. 2007 ; Vol. 37, No. 9. pp. 692-700.
@article{758bac3d63114ad69cf6eab4a0f11ae3,
title = "Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level",
abstract = "Aims: To compare twice-daily interferon (IFN)-β administration and once-daily IFN-α-2b administration as induction therapy in ribavirin combination therapy in chronic hepatitis C with a high viral load of genotype-1b hepatitis C virus (HCV). Methods: Sixty-one chroniche patitis patients with a high viral load of genotype-1b HCV were randomly divided into three groups: group A was given IFN-β 6 MU induction therapy twice daily for 2 weeks; group B was given IFN-α-2b 6 MU induction therapy once daily for 2 weeks; and group C was given no induction therapy. All three groups were then given IFN-α-2b 6 MU 3days/week for the rest of the 24-week study period. Ribavirin was given for the entire 24-week study period. Results: Although the cumulative HCV-RNA negative rates tended to be higher in group A than in group B, the differencewas not significant. The HCV-RNA negative rate at week 2 was significantly higher in groups A and B than in group C (P<0.05). The sustained virological response (SVR) rate was 16{\%} overall, 21{\%} for groups A and B, and 5{\%} for group C; the SVR rate of groups A plus B tended to be higher than that of group C (P=0.093). Conclusions: There was no difference between the effects ofthe two induction therapies; potent induction therapy does achieve higher early viral clearance but not a higher SVR rate.",
keywords = "Chronic hepatitis C, Genotype 1b, Induction therapy, Interferon-α-2b, Interferon-β, Ribavirin",
author = "Shotaro Enomoto and Hideyuki Tamai and Masashi Oka and Naoki Shingaki and Tatsuya Shiraki and Machiko Takeuchi and Hisanobu Deguchi and Hirohito Magari and Izumi Inoue and Mikitaka Iguchi and Kimihiko Yanaoka and Kenji Arii and Mitsuhiro Fujishiro and Naohisa Yahagi and Hiroshi Yotsuyanagi and Masao Ichinose",
year = "2007",
month = "9",
doi = "10.1111/j.1872-034X.2007.00112.x",
language = "English",
volume = "37",
pages = "692--700",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "9",

}

TY - JOUR

T1 - Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level

AU - Enomoto, Shotaro

AU - Tamai, Hideyuki

AU - Oka, Masashi

AU - Shingaki, Naoki

AU - Shiraki, Tatsuya

AU - Takeuchi, Machiko

AU - Deguchi, Hisanobu

AU - Magari, Hirohito

AU - Inoue, Izumi

AU - Iguchi, Mikitaka

AU - Yanaoka, Kimihiko

AU - Arii, Kenji

AU - Fujishiro, Mitsuhiro

AU - Yahagi, Naohisa

AU - Yotsuyanagi, Hiroshi

AU - Ichinose, Masao

PY - 2007/9

Y1 - 2007/9

N2 - Aims: To compare twice-daily interferon (IFN)-β administration and once-daily IFN-α-2b administration as induction therapy in ribavirin combination therapy in chronic hepatitis C with a high viral load of genotype-1b hepatitis C virus (HCV). Methods: Sixty-one chroniche patitis patients with a high viral load of genotype-1b HCV were randomly divided into three groups: group A was given IFN-β 6 MU induction therapy twice daily for 2 weeks; group B was given IFN-α-2b 6 MU induction therapy once daily for 2 weeks; and group C was given no induction therapy. All three groups were then given IFN-α-2b 6 MU 3days/week for the rest of the 24-week study period. Ribavirin was given for the entire 24-week study period. Results: Although the cumulative HCV-RNA negative rates tended to be higher in group A than in group B, the differencewas not significant. The HCV-RNA negative rate at week 2 was significantly higher in groups A and B than in group C (P<0.05). The sustained virological response (SVR) rate was 16% overall, 21% for groups A and B, and 5% for group C; the SVR rate of groups A plus B tended to be higher than that of group C (P=0.093). Conclusions: There was no difference between the effects ofthe two induction therapies; potent induction therapy does achieve higher early viral clearance but not a higher SVR rate.

AB - Aims: To compare twice-daily interferon (IFN)-β administration and once-daily IFN-α-2b administration as induction therapy in ribavirin combination therapy in chronic hepatitis C with a high viral load of genotype-1b hepatitis C virus (HCV). Methods: Sixty-one chroniche patitis patients with a high viral load of genotype-1b HCV were randomly divided into three groups: group A was given IFN-β 6 MU induction therapy twice daily for 2 weeks; group B was given IFN-α-2b 6 MU induction therapy once daily for 2 weeks; and group C was given no induction therapy. All three groups were then given IFN-α-2b 6 MU 3days/week for the rest of the 24-week study period. Ribavirin was given for the entire 24-week study period. Results: Although the cumulative HCV-RNA negative rates tended to be higher in group A than in group B, the differencewas not significant. The HCV-RNA negative rate at week 2 was significantly higher in groups A and B than in group C (P<0.05). The sustained virological response (SVR) rate was 16% overall, 21% for groups A and B, and 5% for group C; the SVR rate of groups A plus B tended to be higher than that of group C (P=0.093). Conclusions: There was no difference between the effects ofthe two induction therapies; potent induction therapy does achieve higher early viral clearance but not a higher SVR rate.

KW - Chronic hepatitis C

KW - Genotype 1b

KW - Induction therapy

KW - Interferon-α-2b

KW - Interferon-β

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=34447325598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447325598&partnerID=8YFLogxK

U2 - 10.1111/j.1872-034X.2007.00112.x

DO - 10.1111/j.1872-034X.2007.00112.x

M3 - Article

VL - 37

SP - 692

EP - 700

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 9

ER -